Budesonide capsules - AstraZeneca

Drug Profile

Budesonide capsules - AstraZeneca

Alternative Names: Budecol; Budesonide CIR capsule; Budesonide Controlled Ilieal Release capsule; D9421-C; Entocir; Entocord; Entocort; Zentacort

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Tillotts Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Proctitis; Ulcerative colitis

Most Recent Events

  • 29 Nov 2016 Launched for Crohn's disease in Japan (PO)
  • 06 Oct 2016 Registered for Crohn's disease in Japan (PO)
  • 28 Sep 2016 Budesonide sub-licensed to PENDOPHARM in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top